ARCT Arcturus Therapeutics Holdings Inc
Company Analysis
Latest News
🔴 Arcturus Therapeutics is trading 10.27% down today after profit-taking following an unusually strong rally
Arcturus Therapeutics is trading 10.27% down at $14.51 after profit-taking following an unusually strong rally. - Shares rose from $10.28 on August 19 to...
🔴 Arcturus Therapeutics is trading 5.4% down today after profit-taking amid cooling biotechnology sentiment
Arcturus Therapeutics is trading 5.4% down now at $15.29, apparently reflecting profit-taking and cooling biotechnology sentiment after substantial gains over...
🟢 Arcturus Therapeutics is trading 5.1% up today ahead of ARCT-810 Phase 2 data
Arcturus Therapeutics is trading 5.1% up now at $16.23, driven primarily by anticipation of clinical data from its experimental mRNA rare-disease programs. -...
Arcturus Nearly Doubles in a Week on mRNA Drug Hopes — But Can a Tiny Biotech Sustain a Rally Built on Data That Hasn't Dropped Yet?
Shares surged as investors placed an aggressive bet that Arcturus Therapeutics will deliver positive results from its experimental mRNA treatment for a rare...
🟢 Arcturus Therapeutics is trading 10.18% up today as company presents new ARCT-810 Phase 2 data
Arcturus Therapeutics is trading 10.18% up now at $15.80 after presenting a scientific poster on its ARCT-810 mRNA therapy for OTC deficiency at the 2026...
🟢 Arcturus Therapeutics is trading 6.6% up today after ARCT-810's Phase 2 enrollment and dosing
Arcturus Therapeutics is trading 6.6% up at $15.29 after renewed investor focus on ARCT-810, its mRNA therapy for OTC deficiency. - Phase 2 enrollment and...
Arcturus Therapeutics Details mRNA Therapy Progress, Shares Rally 60% This Week
Arcturus Therapeutics will present a scientific poster on its ARCT-810 mRNA therapy at a symposium in Helsinki. The presentation details the therapy's impact...
🟢 Arcturus Therapeutics Holdings Inc is trading 6.77% up
ARCT is trading at $14.36, up 6.77%.
🟢 Arcturus Therapeutics is trading 10.6% up today after renewed coverage of regained global KOSTAIVE rights
Arcturus Therapeutics is trading 10.6% up at $12.15 after renewed coverage of its regained global KOSTAIVE rights and broader infectious-disease vaccine...
🟢 Arcturus Therapeutics is trading 8.6% up today after regaining global KOSTAIVE rights
Arcturus Therapeutics is trading 8.6% up at $11.94, following coverage of its regained global rights to KOSTAIVE. - Shares rose 6.91% on August 20 and 25.21%...
🟢 Arcturus Therapeutics Holdings Inc is trading 10.17% up
ARCT is trading at $11.32, up 10.17%.
🟢 Arcturus Therapeutics is trading 5.3% up today amid optimism over returned rights and reduced liabilities
Arcturus Therapeutics is trading 5.3% up at $10.82, with the move appearing to extend investor enthusiasm over the CSL collaboration termination. - On August...
Arcturus Pops 29% on CSL Breakup Gains and Analyst Support — But Can a Cash Cushion Substitute for Revenue?
Shares of Arcturus Therapeutics surged 28.9% to $10.58 on August 19, as investors digested the full implications of a partnership dissolution that,...
🟢 Arcturus Therapeutics is trading 29% up today after CSL settlement returned KOSTAIVE rights
Arcturus Therapeutics is trading 28.87% up now at $10.58 after Canaccord maintained its Buy rating while reducing the price target to $20 from $21. -...
🟢 Arcturus Therapeutics is trading 11% up in pre-market — no clear catalyst identified
Arcturus Therapeutics is trading 10.86% up at $9.10, versus its August 18 close of $8.21, with no clear August 19 company-specific catalyst identified. - The...
🟢 Arcturus Therapeutics is trading 6.62% up today after volatile recent gains
Arcturus Therapeutics is trading 6.62% up at $8.38, extending a volatile advance after recent gains. - It gained 21.88% on August 7 and 6.67% on August 11. -...
🟢 Arcturus Therapeutics is trading 6% up today as broader market advances
Arcturus Therapeutics is trading 5.99% up now at $8.05, outperforming the broader market as U.S. stocks advance and investors show greater risk appetite after...